• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    Central Nervous System Biomarkers Market Research Report—Forecast till 2032 Infographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Central Nervous System Biomarkers Market

    ID: MRFR/HC/7668-HCR
    120 Pages
    Kinjoll Dey
    September 2025

    Central Nervous System Biomarkers Market Research Report Information by Type Procedure (Safety, Efficacy, Validation Biomarker), Application (Drug Discovery & Development, Personalized Medicine), End Use (Diagnostic Labs, Hospitals & Clinics, Research Centers), and Region (North America, Europe, Asia-Pacific, Rest of the World)—Forecast to 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Central Nervous System Biomarkers Market Research Report—Forecast till 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Infographic

    Central Nervous System Biomarkers Market Summary

    The Global Central Nervous System Biomarkers Market is projected to grow significantly from 6.5 USD Billion in 2024 to 15.7 USD Billion by 2035.

    Key Market Trends & Highlights

    Central Nervous System Biomarkers Key Trends and Highlights

    • The market is expected to expand at a compound annual growth rate of 8.35 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 15.7 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 6.5 USD Billion, reflecting the increasing focus on neurological disorders.
    • Growing adoption of advanced diagnostic technologies due to the rising prevalence of neurological diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 6.5 (USD Billion)
    2035 Market Size 15.7 (USD Billion)
    CAGR (2025-2035) 8.35%

    Major Players

    Thermo Fisher Scientific (US), Merck & Co. (US), AbaStarMDx Inc. (US), Abiant, Inc. (US), Avacta Group plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc. (US), Acumen pharmaceuticals Inc. (US), Siemens AG (Germany), Novartis (Switzerland)

    Central Nervous System Biomarkers Market Drivers

    Rising Prevalence of Neurological Disorders

    The increasing incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis drives the Global Central Nervous System Biomarkers Market Industry. As the global population ages, the prevalence of these conditions is expected to rise significantly. For instance, the World Health Organization indicates that by 2030, the number of individuals aged 60 years and older will reach 1.4 billion, highlighting the urgent need for effective diagnostic tools. This growing demand for biomarkers to aid in early diagnosis and treatment monitoring is projected to contribute to the market's growth, with an estimated value of 6.5 USD Billion in 2024.

    Key Companies in the Central Nervous System Biomarkers Market market include

    Industry Developments

      • InSeptember 2020, Siemens Healthineersannounced a strategic collaboration with Novartis Pharma AG for biomarker development for Multiple Sclerosis.
      • In May 2019, N170 CNS biomarker letter of intent submitted by Roche (Switzerland) was accepted by FDA for autism spectrum disorder.
      • In March 2020, Oculomotor Index was accepted by FDA as a valid biomarker for the diagnosis of autism spectrum disorder, submitted by The Autism Biomarkers Consortium for Clinical Trials (ABC-CT).

    Future Outlook

    Central Nervous System Biomarkers Market Future Outlook

    The Central Nervous System Biomarkers Market is projected to grow at an 8.35% CAGR from 2024 to 2035, driven by advancements in diagnostics, increasing prevalence of neurological disorders, and rising demand for personalized medicine.

    New opportunities lie in:

    • Develop innovative biomarker-based diagnostic tools for early detection of neurodegenerative diseases.
    • Invest in AI-driven analytics platforms to enhance biomarker discovery and validation processes.
    • Forge strategic partnerships with pharmaceutical companies to integrate biomarkers in clinical trials.

    By 2035, the Central Nervous System Biomarkers Market is expected to reach substantial growth, reflecting evolving healthcare needs and technological advancements.

    Market Segmentation

    Report Overview:

    Central Nervous System Biomarkers Market Segmentation

    By type
    • {"Safety Biomarker"=>[]}
    By End User
    • {"Diagnostic Labs"=>[]}
    By Application
    • {"Drug Discovery & Development"=>[]}
    Central Nervous System Biomarkers Market Regional Analysis
    • {"North America"=>[]}

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 6.01 (USD Billion)
    Market Size 2024 6.50 (USD Billion)
    Market Size 2032 12.24 (USD Billion)
    Compound Annual Growth Rate (CAGR) 8.67 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Thermo fisher scientific (US), Merck & Co (US), AbaStarMDx Inc (US), Abiant, Inc (US), Avacta Group Plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc (US), Acumen pharmaceuticals Inc (US) and others
      Key Market Opportunities   Untapped APAC region have significant opportunity for CNS biomarker market and rising
      Key Market Drivers   New technological advancements and their increased use in the diagnosis of neurodegenerative diseases   Increase in R&D for new CNS biomarkers and successful clinical trials

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Get In Touch
    Leave a Comment

    FAQs

    What is the valuation of the Central Nervous System Biomarkers Market?

    central nervous system biomarkers market is reachinga market value of USD ~12.24 Billion by 2032

    What is the growth rate of the Central Nervous System Biomarkers Market?

    central nervous system biomarkers market is expected to record a CAGR of ~8.67% during the forecast period 2024-2032

    What are the factors driving the Central Nervous System Biomarkers Market?

    The major factors driving the CNS biomarkers market include new technological advancements and their increased use in the diagnosis of neurodegenerative diseases. Moreover, an increase in R&D for new CNS biomarkers and successful clinical trials further contribute to the market growth.

    What is the leading regional Central Nervous System Biomarkers Market?

    North America is expected to dominate the CNS biomarkers market in 2021, owing to the growing geriatric population, the adoption of the latest technologies for CNS disorder treatment, and key industry players across the region.

    Who are the major players in the Central Nervous System Biomarkers Market?

    Some of the key players in the CNS biomarkers market are Thermo Fisher Scientific (US), Merck & Co. (US), AbaStarMDx Inc. (US), Abiant, Inc. (US), Avacta Group plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc. (US), and Acumen Pharmaceuticals Inc. (US) amongothers.

    Central Nervous System Biomarkers Market Research Report—Forecast till 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    No regional reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027